Review of the state of the art of acrylamide human biomonitoring
Por:
Albiach-Delgado A, Esteve-Turrillas FA, Fernández SF, Garlito B and Pardo O
Publicada:
1 may 2022
Ahead of Print:
1 feb 2022
Resumen:
Human biomonitoring (HBM) is a very useful tool for assessing human exposure to acrylamide (AA). In the framework of the Human Biomonitoring Initiative (HBM4EU) AA was included in its second list of priority substances due to the potential threat to human health. HBM data on AA are scarce, but the use of specific and sensitive biomarkers represents a reliable indicator of exposure. In this review an overview of available knowledge on HBM of AA is provided in terms of: i) preferred exposure biomarkers and matrices for the HBM of AA; ii) analytical methods for determining its biomarkers of exposure in the most used specimens; iii) current HBM data available; and iv) tools for interpreting HBM data for AA in relation to risk assessment. Finally, future trends in this field are discussed.
Filiaciones:
Albiach-Delgado A:
Department of Analytical Chemistry, University of Valencia, Doctor Moliner 50, 46100, Burjassot, Spain
Esteve-Turrillas FA:
Department of Analytical Chemistry, University of Valencia, Doctor Moliner 50, 46100, Burjassot, Spain
:
Department of Analytical Chemistry, University of Valencia, Doctor Moliner 50, 46100, Burjassot, Spain
Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, FISABIO-Public Health, Av. Catalunya, 21, 46020, Valencia, Spain
:
Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, FISABIO-Public Health, Av. Catalunya, 21, 46020, Valencia, Spain
:
Department of Analytical Chemistry, University of Valencia, Doctor Moliner 50, 46100, Burjassot, Spain
Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, FISABIO-Public Health, Av. Catalunya, 21, 46020, Valencia, Spain
hybrid
|